Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Trial Profile

A Phase II Study of Sodium Cridanimod in Conjunction With Progestin Therapy in Patients With Progesterone Receptor Negative Recurrent or Persistent Endometrial Carcinoma

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cridanimod (Primary) ; Medroxyprogesterone; Megestrol
  • Indications Adenocarcinoma; Carcinoma; Endometrial cancer
  • Focus Therapeutic Use
  • Sponsors AS Kevelt
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 23 Jan 2017 Status changed from recruiting to active, no longer recruiting.
    • 19 Aug 2016 According to Xenetic Biosciences media release, an Investigational New Drug (IND) application for the Company's product candidate, Virexxa (sodium cridanimod), has been allowed to proceed by the U.S. Food and Drug Administration (FDA).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top